Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) shot up 7.5% during mid-day trading on Tuesday . The stock traded as high as $5.17 and last traded at $5.04, with a volume of 223,675 shares changing hands. The stock had previously closed at $4.69.

Several brokerages have issued reports on AGLE. Wells Fargo & Co. began coverage on shares of Aeglea Biotherapeutics in a report on Monday, May 2nd. They issued an “outperform” rating on the stock. BMO Capital Markets began coverage on shares of Aeglea Biotherapeutics in a report on Monday, May 2nd. They issued an “outperform” rating and a $19.00 price target on the stock. Needham & Company LLC began coverage on shares of Aeglea Biotherapeutics in a report on Monday, May 9th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, Zacks Investment Research raised shares of Aeglea Biotherapeutics from a “sell” rating to a “hold” rating in a report on Wednesday.

The firm has a 50 day moving average of $4.66 and a 200-day moving average of $6.59. The stock’s market cap is $79.12 million.

Aeglea Biotherapeutics (NASDAQ:AGLE) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.03. On average, equities research analysts expect that Aeglea Biotherapeutics Inc. will post ($4.77) earnings per share for the current year.

Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.